Drug intelligence / Profile preview

GPCR 5 program

Development stage: Preclinical
Lead developer: Superluminal Medicines
Modality: Small Molecules

Overview

GPCR 5 is a preclinical drug candidate being developed by Superluminal Medicines. It is a small-molecule biased ligand designed to modulate the signaling of an undisclosed G protein-coupled receptor (GPCR). By utilizing a biased signaling approach, the compound is engineered to selectively activate or inhibit specific downstream intracellular pathways associated with the target GPCR, potentially enhancing therapeutic efficacy while reducing side effects compared to traditional balanced ligands. The program is currently in the hit-to-lead stage of development and is intended for the treatment of endocrine and cardiometabolic diseases.

Other names: Superluminal Medicines-undisclosed GPCR-small molecule-biased ligand

Beyond the preview

Go deeper on GPCR 5 program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPCR 5 program.

Explore the full profile